Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Magenta Therapeutics Inc
(NQ:
MGTA
)
8.210
USD
-0.080 (-0.97%)
Official Closing Price
Updated: 4:03 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
151,500
Open
8.180
Bid (Size)
8.000 (1)
Ask (Size)
8.700 (3)
Prev. Close
8.290
Today's Range
8.100 - 8.401
52wk Range
5.760 - 14.25
Shares Outstanding
34,370,267
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Anne McGeorge, Former Managing Partner of Grant Thornton LLP, Joins CitiusTech’s Board of Directors and Chair of the Audit Committee
January 12, 2021
CitiusTech, a leading provider of healthcare technology services and solutions, announced today that Anne McGeorge, former Managing Partner of Grant Thornton’s Global Health Care and Life Sciences...
From
Business Wire News Releases
Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials
January 11, 2021
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more...
From
Business Wire News Releases
Performance
YTD
+7.18%
+7.18%
1 Month
+6.62%
+6.62%
3 Month
+21.63%
+21.63%
6 Month
+9.91%
+9.91%
1 Year
-40.68%
-40.68%
More News
Read More
Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021
From
Business Wire News Releases
Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditionin
December 07, 2020
From
Business Wire News Releases
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell
December 04, 2020
From
Business Wire News Releases
Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer
November 09, 2020
From
Business Wire News Releases
Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results
November 05, 2020
From
Business Wire News Releases
Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting
November 04, 2020
From
Business Wire News Releases
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September
September 11, 2020
From
Business Wire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
July 15, 2020
From
GlobeNewswire News Releases
Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV
September 02, 2020
From
Business Wire News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.